Get the Stockscreener App
6.06
2.54%
0.15
Artiva Biotherapeutics Inc stock is traded at $6.06, with a volume of 416.76K.
It is up +2.54% in the last 24 hours and down -31.99% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$5.91
Open:
$5.93
24h Volume:
416.76K
Relative Volume:
0.91
Market Cap:
$296.27M
Revenue:
$251.00K
Net Income/Loss:
$-87.07M
P/E Ratio:
-1.7073
EPS:
-3.5494
Net Cash Flow:
$-80.18M
1W Performance:
-10.88%
1M Performance:
-31.99%
6M Performance:
-33.41%
1Y Performance:
+101.33%
1-Day Range:
$5.85
$6.16
1-Week Range:
$5.85
$7.135
52-Week Range:
$2.71
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
6.06 | 296.27M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Artiva Biotherapeutics' CTO Christopher Horan Sells 10,340 Shares to Cover RSU Tax Withholding - Kalkine Media
Artiva Biotherapeutics, Inc. (ARTV) stock price, news, quote and history - Yahoo Finance UK
Alpha Cognition Inc. Common Stock (ACOG) Stock Price, News, Quote & History - Yahoo! Finance Canada
A cell treatment and a drug depleted antibody-making immune cells in 60 people with rheumatic diseases - Stock Titan
Artiva Biotherapeutics (NASDAQ: ARTV) Grants CEO Aslan Fred 315,000 Derivative Securities and 110,000 Shares - Kalkine Media
Artiva Biotherapeutics (NASDAQ: ARTV) Increases 2024 Equity Incentive Plan by Over 5 Million Shares - Kalkine Media
Director gets 16,250 stock options at $10.42 at Artiva (ARTV) - Stock Titan
Artiva Biotherapeutics Expands Equity Plan, Elects Directors - The Globe and Mail
Artiva (ARTV) boosts R&D head's stake with 135K new options - Stock Titan
Artiva Biotherapeutics Expands Equity Plan, Elects Directors - TipRanks
Shareholders back more stock awards at Artiva (ARTV) - Stock Titan
Artiva Biotherapeutics (ARTV) CEO Fred Aslan Sells 23,429 Shares - GuruFocus
Artiva Biotherapeutics CEO Fred Aslan Executes Sale of 23,429 Shares Under 10b5-1 Plan - Kalkine Media
ARTV: Pivotal phase III trial in refractory RA advances, aiming for first-in-class deep B-cell depletion - TradingView
Artiva Biotherapeutics at cantor healthcare conference: ra push gains ground By Investing.com - Investing.com Canada
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics Insider Sold Shares Worth $255,746, According to a Recent SEC Filing - Yahoo Finance
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 - TradingView
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com UK
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® - GlobeNewswire
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - WBOC TV
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - Yahoo Finance
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com India
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatOperating Income Trends - vinanet.vn
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com UK
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower Loss of $0.63 per Share, But Stock Slips 0.35%Debt Analysis Report - vinanet.vn
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FRED ASLAN | Director |
Oct 06 '26 |
Proposed Sale |
7.13 |
34,465 |
245,735 |
0 |
| Bush Jennifer | COO, CLO, Compliance Officer |
Oct 05 '26 |
Sale |
6.84 |
8,370 |
57,227 |
366,159 |
| Banerjee Subhashis | Chief Medical Officer |
Oct 05 '26 |
Sale |
6.84 |
1,099 |
7,514 |
169,848 |
| Horan Christopher | Chief Tech Operations Officer |
Oct 05 '26 |
Sale |
6.84 |
10,340 |
70,697 |
312,744 |
| Aslan Fred | Chief Executive Officer |
Oct 05 '26 |
Sale |
6.84 |
61,696 |
421,828 |
1,543,069 |
| Aslan Fred | Chief Executive Officer |
Sep 08 '26 |
Sale |
10.92 |
23,429 |
255,746 |
1,449,765 |
| FRED ASLAN | Director |
Sep 08 '26 |
Proposed Sale |
11.19 |
23,429 |
262,171 |
0 |
| Horan Christopher | Chief Tech Operations Officer |
Sep 03 '26 |
Sale |
11.16 |
10,366 |
115,638 |
283,084 |
| Bush Jennifer | COO, CLO, Compliance Officer |
Sep 03 '26 |
Sale |
11.16 |
8,391 |
93,606 |
329,529 |
| Banerjee Subhashis | Chief Medical Officer |
Sep 03 '26 |
Sale |
11.16 |
1,100 |
12,271 |
140,947 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):